Walleye Capital
NVS icon

Walleye Capital’s Novartis NVS Stock Holding History

Walleye Capital’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.6M Buy
169,600
+13,100
+8% +$1.96M 0.1% 178
2026
Q1 		$23.9M Sell
156,500
-79,000
-34% -$12.1M 0.1% 146
2025
Q4 		$32.5M Buy
235,500
+35,600
+18% +$4.66M 0.1% 131
2025
Q3 		$25.6M Buy
199,900
+159,800
+399% +$19.5M 0.1% 178
2025
Q2 		$4.85M Buy
40,100
+32,200
+408% +$3.63M 0.02% 881
2025
Q1 		$881K Sell
7,900
-2,600
-25% -$277K ﹤0.01% 2075
2024
Q4 		$1.02M Sell
10,500
-181,500
-95% -$19.4M ﹤0.01% 2374
2024
Q3 		$22.1M Buy
192,000
+50,700
+36% +$5.75M 0.05% 301
2024
Q2 		$15M Buy
141,300
+33,700
+31% +$3.38M 0.03% 515
2024
Q1 		$10.4M Sell
107,600
-166,700
-61% -$17.1M 0.02% 806
2023
Q4 		$27.7M Buy
274,300
+99,500
+57% +$9.6M 0.06% 233
2023
Q3 		$17.8M Buy
174,800
+97,100
+125% +$9.86M 0.05% 304
2023
Q2 		$7.84M Buy
77,700
+54,400
+233% +$5.44M 0.03% 506
2023
Q1 		$2.14M Buy
+23,300
New +$2.03M 0.03% 682

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Walleye Capital's NVS Position: Q2 2026 in Review

Walleye Capital sold out of Novartis (NVS) in Q2 2026, closing a stake of 13,734 shares — an estimated $2.06M sold.

Walleye Capital first reported a position in NVS in Q3 2018 and held it in 10 quarters. The position peaked at $3.37M in Q3 2024. 1,621 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Walleye Capital reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 13,734 Novartis shares in Q2 2026, an estimated $2.06M.
  • Walleye Capital first reported a position in Novartis in Q3 2018 and held it in 10 quarters.
  • Walleye Capital's Novartis position peaked at $3.37M in Q3 2024.
  • 1,621 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.